Therapy With Oncolytic Viruses Progress And Challenges Sophia Z Shalhout David M Miller Kevin S Emerick Howard L Kaufman by Sophia Z. Shalhout & David M. Miller & Kevin S. Emerick & Howard L. Kaufman instant download after payment.

Oncolytic viruses (OVs) are an emerging class of cancer therapeutics Introductionthat ofer the benefts of selective replication in tumour cells, delivery Clinical developmentof multiple eukaryotic transgene payloads, induction of immunogenic Neoadjuvant therapycell death and promotion of antitumour immunity, and a tolerable Combination therapiessafety profle that largely does not overlap with that of other cancer therapeutics. To date, four OVs and one non-oncolytic virus have been Challenges in clinical developmentapproved for the treatment of cancer globally although talimogene Promising novel OVslaherparepvec (T-VEC) remains the only widely approved therapy. T-VEC is indicated for the treatment of patients with recurrent melanoma Conclusionsafter initial surgery and was initially approved in 2015. An expanding body of data on the clinical experience of patients receiving T-VEC is now becoming available as are data from clinical trials of various other OVs in a range of other cancers. Despite increasing research interest, a better understanding of the underlying biology and pharmacology of OVs is needed to enable the full therapeutic potential of these agents in patients with cancer. In this Review, we summarize the available data and provide guidance on optimizing the use of OVs in clinical practice, with a focus on the clinical experience with T-VEC. We describe data on selected novel OVs that are currently in clinical development, either as monotherapies or as part of combination regimens. We also discuss some of the preclinical, clinical and regulatory hurdles that have thus far limited the development of OVs.